Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2000

View Archived Issues

Xechem awarded SBIR grant for marine extremophile research

Phase I trial shows excellent safety profile for NeoRx's STR agent

Avant Immunotherapeutics reports on TP-10 progress

Tripos and Parke-Davis to jointly develop high-throughput screening methods

Inflazyme selects nonemetic PDE4 inhibitor, updates status of other products

Enzo Biochem receives grant for HBV therapy

Provigil under study for several indications

TXU (anti-CD7)-PAP possesses good pharmacokinetics, low toxicity

AxyS announces combinatorial chemistry agreement with Searle

Hollis-Eden product shows efficacy in chloroquine-resistant malaria

IL-5 receptor antagonists discovered at Structural Bioinformatics

Therapeutically useful substituted oxazolidinones emerge from R&D at AstraZeneca

New beta-carbolines are somatostatin receptor ligands and sodium channel blockers

SB discloses newest selective dopamine D3 receptor ligands

Distamycin derivatives in development at Pharmacia & Upjohn

Glycine-antagonist tetrahydroquinoline derivatives designed at Glaxo Wellcome

Byk Gulden patents new PDE4 inhibitors

Merck KGaA designs nontoxic hypoglycemic agents particularly useful for NIDDM

Efforts at DuPont to design potent and selective alphavbeta3 antagonists successful

CKD-731: new fumagillin analogue shows potential as antiangiogenic agent

Antiplatelet agent OPC-29030 appears to act by inhibiting 12-lipoxygenase translocation

FemSoft Insert now commercially available in U.S. for treatment of incontinence

Avax Technologies' O-Vax IND accepted

First clinical results with 90Y-DOTATOC indicate antitumor efficacy, some safety problems

KeraVision commences clinical trials for use of Intacs as treatment of keratoconus

Avant's cholera vaccine to enter phase IIb trial

HIV gene medicine from Enzo progresses favorably in phase I trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...